A novel first-line maintenance therapy regimen improved outcomes for patients with extensive-stage small cell lung cancer, according to study results scheduled for presentation at ASCO Annual ...

A new class of molecules capable of killing the cancer cells that are refractory to standard treatments and responsible for recurrence has just been developed. This crucial advance in the fight ...

Abbvie (($ABBV)) announced an update on their ongoing clinical study. AbbVie is conducting a clinical study titled Phase 2/3 Open Label Randomized ...